Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Treatment That Can Be Taken at Home for Myelodysplastic Syndrome Receives FDA Approval

A New Treatment That Can Be Taken at Home for Myelodysplastic Syndrome Receives FDA Approval

Decitabine and cedazuridine (Inqovi) tablets received US Food and Drug Administration (FDA) approval on 7 July 2020 for the treatment of adult patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). This represents an important advance in treatment options for patients with MDS, a type of blood cancer, who previously had to visit a healthcare facility to receive intravenous treatment (through a vein).

The ASTX727-01-B Trial

The approval is based on clinical trial results showing similar drug concentrations with intravenous decitabine and Inqovi. In addition, approximately half of the patients who had previously been transfusion-dependent were able to go without a transfusion over an 8-week period.

Inqovi's safety profile was also similar to that of intravenous decitabine. Some common side effects of Inqovi include fatigue, constipation, bleeding, muscle pain, mucositis (mouth sores), arthralgia (joint pain), nausea, and fever with a low white blood cell count.

Inqovi can cause fetal harm (harm to an unborn baby), and male and female patients of reproductive age are advised to use effective contraception (birth control). Inqovi is taken orally as one tablet once daily on the first 5 days of each 28-day cycle.

Sources

FDA approves oral combination of decitabine and cedazuridine for myelodysplastic syndromes.
fda.gov - 7 July 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Treatment That Can Be Taken at Home for Myelodysplastic Syndrome Receives FDA Approval

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy